TSE:4519 (Japan)
Business Description
Chugai Pharmaceutical Co Ltd
NAICS : 325412
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Description
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines, primarily focused on oncology, renal diseases, and bone and joint diseases. It is an industry leader in antibody technology with several notable therapies, including Hemlibra for hemophilia patients and Actemra for rheumatoid arthritis.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.8 | |||||
| Interest Coverage | 10342.74 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 14.15 | |||||
| Beneish M-Score | -2.36 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 19.9 | |||||
| 3-Year EBITDA Growth Rate | 51.1 | |||||
| 3-Year EPS without NRI Growth Rate | 48.5 | |||||
| 3-Year FCF Growth Rate | 70.9 | |||||
| 3-Year Book Growth Rate | 16.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 1.42 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 4.41 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.04 | |||||
| 9-Day RSI | 58.26 | |||||
| 14-Day RSI | 56.87 | |||||
| 6-1 Month Momentum % | -10.28 | |||||
| 12-1 Month Momentum % | -10.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.83 | |||||
| Quick Ratio | 3.08 | |||||
| Cash Ratio | 2.01 | |||||
| Days Inventory | 188.01 | |||||
| Days Sales Outstanding | 93.83 | |||||
| Days Payable | 114.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.23 | |||||
| Dividend Payout Ratio | 0.36 | |||||
| 3-Year Dividend Growth Rate | 46.8 | |||||
| Forward Dividend Yield % | 2.02 | |||||
| 5-Year Yield-on-Cost % | 13.15 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 66.08 | |||||
| Operating Margin % | 45.46 | |||||
| Net Margin % | 32.26 | |||||
| ROE % | 33.09 | |||||
| ROA % | 26.36 | |||||
| ROIC % | 47.27 | |||||
| ROC (Joel Greenblatt) % | 87.75 | |||||
| ROCE % | 45.54 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 15.94 | |||||
| Forward PE Ratio | 19.84 | |||||
| PE Ratio without NRI | 15.94 | |||||
| Shiller PE Ratio | 47.22 | |||||
| Price-to-Owner-Earnings | 21.78 | |||||
| PEG Ratio | 0.37 | |||||
| PS Ratio | 5.14 | |||||
| PB Ratio | 4.74 | |||||
| Price-to-Tangible-Book | 4.84 | |||||
| Price-to-Free-Cash-Flow | 18.28 | |||||
| Price-to-Operating-Cash-Flow | 14.68 | |||||
| EV-to-EBIT | 10.29 | |||||
| EV-to-Forward-EBIT | 13.34 | |||||
| EV-to-EBITDA | 10.29 | |||||
| EV-to-Forward-EBITDA | 12.45 | |||||
| EV-to-Revenue | 4.65 | |||||
| EV-to-Forward-Revenue | 5.11 | |||||
| EV-to-FCF | 16.53 | |||||
| Price-to-Projected-FCF | 2.11 | |||||
| Price-to-DCF (Earnings Based) | 0.42 | |||||
| Price-to-DCF (FCF Based) | 0.7 | |||||
| Price-to-Median-PS-Value | 1.03 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.64 | |||||
| Price-to-Graham-Number | 1.85 | |||||
| Price-to-Net-Current-Asset-Value | 7.67 | |||||
| Price-to-Net-Cash | 22.63 | |||||
| Earnings Yield (Greenblatt) % | 9.72 | |||||
| Forward Rate of Return (Yacktman) % | 22.38 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 1,205,697 | ||
| EPS (TTM) (円) | 236.44 | ||
| Beta | 0.89 | ||
| Volatility % | 23.63 | ||
| 14-Day RSI | 56.87 | ||
| 14-Day ATR (円) | 91.439899 | ||
| 20-Day SMA (円) | 3703.05 | ||
| 12-1 Month Momentum % | -10.93 | ||
| 52-Week Range (円) | 3258 - 4490 | ||
| Shares Outstanding (Mil) | 1,644.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Chugai Pharmaceutical Co Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||